Contact

Dr. Hans-Jürgen Pietzsch
Head Radionuclide Theragnostics
h.j.pietzschAthzdr.de
Phone: +49 351 260 - 2706, 3045
Fax: 12706, 3232

Radiopharmaceutical treatment of cancer: Development of novel peptide-/antibody-based theragnostics

Diagnosis of tumours and metastases using PET and SPECT as well as radioimmunotherapy requires radiopharmaceuticals which should have high tumour accumulation, high specificity and a fast blood clearance.

    In this scope, our group is designing
  • new bifunctional chelators which are able to bind radiometals with high complex stabilities,

  • versatile linkers for conjugation purposes and

  • modified tumor specific target molecules, such as peptides and antibody-based entities.

These building blocks are joined together to form new immunoconjugates in order to meet the above mentioned requirements.

The choice of the desired radiometal to be applied in future studies determines the nature of the chelator of the radiopharmaceutical. With the choice of the linker, different parameters of the resulting conjugate can be controlled, i.e. the solubility, the distance between the two entities to be coupled, reduction of sterical hindrance during coupling reaction, introduction of further functionalities as well as pharmacokinetic and –dynamic properties, when conjugates are designed for in-vivo applications. The targeting entity has to bind with high affinity and specificity to epitopes overexpressed on tumor cells. The choice of the target / targeting entity is determined by the the cancer type for which the radiopharmaceutical will be designed. We actually use Epithelial Growth Factor Receptor-specific peptides and antibodies for diagnosis and therapy of head and neck squamous cell carcinomas (HNSCC).

After chemical and physical characterisation of the compounds, in vitro and in vivo testing of radiolabelled promising candidates is performed. Our goal is to use these compounds for radioimmunotherapy (internal irradiation) and in combination with radiotherapy (external X-ray irradiation).

We propose for summer school students organic synthetic work in this area of radiopharmaceutical development.


Contact

Dr. Hans-Jürgen Pietzsch
Head Radionuclide Theragnostics
h.j.pietzschAthzdr.de
Phone: +49 351 260 - 2706, 3045
Fax: 12706, 3232